168 related articles for article (PubMed ID: 25267727)
21. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
[TBL] [Abstract][Full Text] [Related]
22. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG).
Porzig A; Matthay KK; Dubois S; Pampaloni M; Damon L; Hawkins R; Goldsby R; Hollinger F; Fitzgerald P
Horm Metab Res; 2012 Jun; 44(7):539-42. PubMed ID: 22588707
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
[TBL] [Abstract][Full Text] [Related]
24. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?
Taïeb D; Sebag F; Hubbard JG; Mundler O; Henry JF; Conte-Devolx B
Clin Endocrinol (Oxf); 2004 Jul; 61(1):102-8. PubMed ID: 15212651
[TBL] [Abstract][Full Text] [Related]
25. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study.
Kotecka-Blicharz A; Hasse-Lazar K; Handkiewicz-Junak D; Gawlik T; Pawlaczek A; Oczko-Wojciechowska M; Michalik B; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2018; 69(3):246-251. PubMed ID: 29645065
[TBL] [Abstract][Full Text] [Related]
26. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
27. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
28. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
29. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy.
Castellani MR; Seghezzi S; Chiesa C; Aliberti GL; Maccauro M; Seregni E; Orunesu E; Luksch R; Bombardieri E
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):100-13. PubMed ID: 20168292
[TBL] [Abstract][Full Text] [Related]
30. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
Mulholland N; Chakravartty R; Devlin L; Kalogianni E; Corcoran B; Vivian G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2002-12. PubMed ID: 26142730
[TBL] [Abstract][Full Text] [Related]
32. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
[TBL] [Abstract][Full Text] [Related]
33. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
34. [131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences].
Hasse-Lazar K; Krajewska J; Paliczka-Cieślik E; Jurecka-Lubieniecka B; Michalik B; Handkiewicz-Junak D; Roskosz J; Jarzab B
Endokrynol Pol; 2008; 59(3):235-40. PubMed ID: 18615399
[TBL] [Abstract][Full Text] [Related]
35. Routine preoperative (123)I-MIBG scintigraphy for patients with phaeochromocytoma is not necessary.
Mihai R; Gleeson F; Roskell D; Parker A; Sadler G
Langenbecks Arch Surg; 2008 Sep; 393(5):725-7. PubMed ID: 18663465
[TBL] [Abstract][Full Text] [Related]
36. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
[TBL] [Abstract][Full Text] [Related]
37. Stable disease and improved health-related quality of life (HRQoL) following fractionated low dose 131I-metaiodobenzylguanidine (MIBG) therapy in metastatic paediatric paraganglioma: observation on false "reverse" discordance during pre-therapy work up and its implication for patient selection for high dose targeted therapy.
Basu S; Nair N
Br J Radiol; 2006 Aug; 79(944):e53-8. PubMed ID: 16861319
[TBL] [Abstract][Full Text] [Related]
38. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Pandit-Taskar N; Chen CC
Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501
[TBL] [Abstract][Full Text] [Related]
39. Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
Jimenez C; Lu Y
Clin Nucl Med; 2023 May; 48(5):426-427. PubMed ID: 36728291
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]